Karl Dane Wittrup

Dr. Wittrup co-founded Ankyra in 2019 after conducting years of research in the field of molecular bioengineering. He is currently the C.P. Dubbs Professor of Chemical Engineering and Biological Engineering at MIT where his research has been responsible for many recent advances in the directed evolution of biopharmaceutical proteins as well as the display of libraries of antibodies and other binding reagents in yeast. Dr. Wittrup’s research interests primarily focus on cancer immunotherapy using engineered cytokines and antibodies. Dr. Wittrup is co-founder and Chairman of the SAB at Adimab, as well as co-founder of Eleven Biotherapeutics.

He is a member of the National Academy of Engineering and previously served as an Associate Director at the Koch Institute for Integrative Cancer Research at MIT. His previous teaching experience includes his service as the J.W. Westwater Professor of Chemical Engineering, Biophysics, and Bioengineering at the University of Illinois at Urbana-Champaign. He obtained both his Ph.D. and an MS in Chemical Engineering from the California Institute of Technology and his BS in Chemical Engineering from the University of New Mexico.